ENGLEWOOD, CO, December 8, 2020 – Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced today that the Company will conduct its annual meeting in a virtual format only on December 12, 2020 at 9:00 am MST. Additional details regarding the meeting are as follows:
Annual Meeting Webcast Link and Call-in Number:
Webcast link: www.virtualshareholdermeeting.com/AMPE2020
U.S./Canada toll-free number: 1-877-328-2502
Please note that the call-in line and webcast link will be muted for the duration of the meeting; however, shareholders will be able to submit their votes and/or questions via the webcast as long as they have their 16-digit control number, which was previously provided on their proxy statement.
An audio replay of the annual meeting will be posted on the Company’s website within 24 hours of the meeting (https://ampiopharma.com/investors/presentations-media).
Forward Looking Statements
Ampio’s statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. Forward-looking statements can be identified by the use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s expectations with respect to the safety and efficacy of Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biologics License Application (BLA), the ability of Ampio to enter into partnering or licensing arrangements, current or future clinical trials, changes in business conditions and similar events (including currently unforeseen risks associated with COVID-19), the possibility that Ampion may be used to treat ARDS induced by COVID-19, Ampio’s ability to continue as a going concern and its ability to continue to raise funds using its “at-the-market” equity offering or otherwise, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, in Ampio’s Annual Report on Form 10-K for the period ended December 31, 2019, and in subsequent reports on Forms 10-Q and 8-K and other filings made by Ampio with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on these forward-looking statements. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.